InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
81.88
(
0.00%
)
Bitcoin
67,069.90
(
-0.15%
)
Post# of 252642
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120081
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 62946

Monday, 07/07/2008 3:19:59 AM

Monday, July 07, 2008 3:19:59 AM

Post# of 252642
MNTA: Teva’s phase-3 trial of the 40mg dose of Copaxone in MS failed to show any benefit vs the standard 20mg dose:

http://www.reuters.com/article/marketsNews/idINBNG13619120080707

This is modestly good news for MNTA in that Teva’s US patents on the 40mg dose might have harder to overturn or circumvent than the patents on the standard 20mg dose. (MNTA is developing a generic version of Copaxone with its partner, NVS.)



Let’s talk biotech!
What if there were no hypothetical questions?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up